We revealed a remarkable instability of HER2 expression from primary breast cancer to residual disease, which indicating that regular retesting of HER2-low status in residual disease should be performed to guide further clinical anti-HER2 ADC therapy. The gene discussed is ERBB2; the disease is breast cancer.